Drug facts
BrandRinvoq (Upadacitinib)
No generic upadacitinib is approved; the latest Rinvoq patent or exclusivity in the Orange Book runs to 03/09/2038. 1 staged generic application passed FDA review and waits on patents or exclusivity.
Rinvoq was first approved by the FDA on 08/16/2019 under NDA 211675; the application holder is Abbvie Inc.
The latest NADAC for RINVOQ ER 15 MG TABLET is $229.50 per unit (as of 10/28/2026).
Holder Abbvie IncApplication NDA 211675Approved 08/16/2019
01Patents and exclusivity
When competition can legally begin. A generic can launch once both exclusivity and the last listed patent expire, unless a court or settlement says otherwise.
4,147days until the latest patent expires
ExclusivityPatent onlyOpen to generics
Today
Approved08/16/2019
Exclusivity ends04/28/2032
Last patent03/09/2038
2020202320262029203220352038
- Latest patent
- 03/09/2038Rinvoq Orange Book
- Exclusivity
- 04/28/2032Rinvoq Orange Book
02Competition
- Generics
- No generic approved Orange Book
- Staged generics
- 1 passed FDA review, awaiting market entry FDA
Every listingEach listing and maker behind the generics count.
Price erosionHow NADAC moves as generics enter.
PrescribersWho prescribes it, from Medicare data.
Available in the full Rinvoq profile.See what is included
03Supply and price
- FDA drug shortage
- ClearNot on the current shortage list FDA shortages
- NADAC
- $229.50 per unitRINVOQ ER 15 MG TABLET, mid-priced of 3 strengths, as of 10/28/2026 CMS NADAC
04Product
- Application holder
- Abbvie Inc Orange Book
- Application
- NDA 211675 Orange Book
- First approved
- 08/16/2019 Orange Book
- Dosage forms
- tablet, extended release
- Routes
- oral
- Other brand names
- Rinvoq LQ
Sources: FDA Orange Book, FDA Purple Book, FDA drug shortages, FDA enforcement reports and CMS NADAC, read through QOPE. Not medical or legal advice.